Medipost is teaming up with Woongjin Free Life to expand its cell storage services.
On August 11, Medipost announced that it will offer a new cell storage conversion service to existing customers of Woongjin Free Life.
This collaboration aims to broaden customer options in the healthcare sector, moving beyond traditional funeral services as interest in health management grows. Customers of Woongjin Free Life will be able to utilize Medipost's cell storage services through the product conversion service.
The conversion service includes two types of products: adipose stem cell storage and immune cell storage. After Woongjin Free Life provides information about the service and procedures, interested customers will be connected to Medipost, which will handle the contracts and storage processes.
Collection of adipose tissue and peripheral blood will be performed by specialized medical personnel from partner medical institutions, while Medipost will be responsible for cell separation, testing, processing, and long-term storage.
A Medipost representative stated, "We expect the synergy between Woongjin Free Life's customer service foundation and Medipost's cell technology and operational capabilities to be significant. We will continue to expand differentiated healthcare services to help customers prepare for a healthy future."
Meanwhile, Medipost has completed Phase 3 clinical trials for its knee osteoarthritis stem cell treatment, Cartistem, in Japan and is currently working on the necessary procedures to apply for product approval by the end of this year.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.